Target Name: MIR491
NCBI ID: G574444
Other Name(s): MicroRNA 491 | microRNA 491 | mir-491 | hsa-miR-491-5p | MIRN491 | hsa-miR-491-3p | hsa-mir-491

MIR491: A Non-Code RNA Drug Target and Biomarker for Cancer

MicroRNA (miRNA) 491 (MIR491) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. MIR491 is a part of the miRNA family, which consists of 21 non-coding RNAs that have been shown to play a critical role in post-transcriptional gene regulation.

MIR491 is characterized by its unique 29 base pair length and its ability to interact with several protein-coding genes, including the nuclear factor of activating T-cell kinases (NFAT), which is a transcription factor that plays a role in the development and regulation of T-cell lineage. NFAT has been shown to play a key role in the development of various types of cancer, including breast, lung, and ovarian cancer.

MIR491 has been shown to regulate the activity of NFAT, which is thought to contribute to its potential as a drug target. By inhibiting the activity of NFAT, MIR491 has been shown to reduce the number of NFAT-regulated genes and to increase the level of gene expression that is not regulated by NFAT. This has led to the hypothesis that MIR491 may be a useful drug target for cancer treatment.

In addition to its potential as a drug target, MIR491 has also been shown to be a potential biomarker for cancer. The expression of MIR491 has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that MIR491 may be a useful biomarker for the diagnosis and monitoring of cancer.

The identification of MIR491 as a potential drug target and biomarker for cancer has important implications for the development of new cancer therapies. MIR491 has been shown to be a strong candidate for small molecule inhibitors, which are drugs that can bind to MIR491 and prevent its interaction with NFAT. These inhibitors have the potential to be used to treat a wide range of cancer types, including breast, lung, and ovarian cancer.

In conclusion, MIR491 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique 29 base pair length and ability to interact with several protein-coding genes, including NFAT, make it an attractive candidate for small molecule inhibitors. Further research is needed to fully understand the potential of MIR491 as a drug target and biomarker for cancer.

Protein Name: MicroRNA 491

More Common Targets

MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193 | MIR5194 | MIR5195 | MIR5196 | MIR5197 | MIR519A1 | MIR519A2 | MIR519B | MIR519C | MIR519D | MIR519E | MIR520A | MIR520B | MIR520C | MIR520D | MIR520E | MIR520F | MIR520G | MIR520H